Cathy Eng, VICC Associate Director, Strategic Relations and Research Partnerships at Vanderbilt-Ingram Cancer, shared a post on X:
“Colorectal cancer posters today at ESMO25.
Our pooled analysis of Fruquintinib AEs, but as our data with tislelizumab. My patient was in cCR for> 2 years.
The best part is seeing my colleagues.”
Follow the latest ESMO 2025 news on OncoDaily.